newsfilter
← Latest News
ACCESS Newswire·

XPhyto Pursues Potential Application of its Oral Dissolvable Biosensor Inflammation Test for Buprenorphine-related Dental Disease

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / July 15, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY),(OTCQB:XPHYF), (FSE:4XT) ("XPhyto" or the "Company") is pleased to report a significant potential market opportunity for its oral dissolvable ("ODF